EPISODE · Oct 28, 2022 · 59 MIN
Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
from PeerView Clinical Pharmacology CME/CNE/CPE Video · host PVI, PeerView Institute for Medical Education
Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches
What this episode covers
Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches
NOW PLAYING
Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
No transcript for this episode yet
Similar Episodes
No similar episodes found.